How Neuralink's brain-interface research and trials unfolded
Trace the research platform, the first human trial, a disclosed implant setback and expansion into new studies. Company reports of participant experience are kept distinct from regulatory approval and established clinical benefit.
31 October 2019 to 29 October 2026 · 16 dated events · 16 sources
Status in the record · 29 October 2026
Neuralink's 29 October 2026 engineering report describes prototype communication features tested with a VOICE participant. Its devices remain investigational, according to that report. The results describe early research and individual experience, not established benefit for every patient or an approved treatment.
Coverage through29 October 2026Editorial review3 November 2026
Overview · 31 Oct 2019 to 29 Oct 2026 · click a dot to jump
16 events shown
2019
31 Oct 2019
Turning point
Start
Neuralink publishes its early research platform
A paper credited to Elon Musk and Neuralink described flexible electrode threads, a surgical insertion robot and an experimental brain-machine interface platform. This was a research publication, not evidence of an approved human treatment.
The company receives permission for an investigational study
Neuralink's later recruitment announcement states that the FDA awarded an investigational device exemption in May 2023. The exemption concerned conducting research, rather than commercial approval of the implant.
Neuralink announced recruitment for PRIME after approval from the reviewing institutional board and its first hospital site. The study was designed to evaluate implant and surgical-robot safety and initial functionality for controlling external devices.
Neuralink's April update dates its first human implant to January 2024 at Barrow Neurological Institute. It identifies neurosurgeon Francisco A. Ponce as principal investigator for the study at Barrow.
Neuralink discloses retracted threads and a software response
The company reported that threads had retracted from the first participant's brain in the weeks after surgery, reducing the number of effective electrodes and performance. It said changes to signal processing, cursor control and the interface subsequently improved performance. This report does not establish that the underlying implant issue was eliminated.
A second participant update describes changed surgical precautions
Neuralink reported that its second participant received an implant in July. It described measures to reduce brain movement and the implant-to-brain gap, and said no thread retraction had been observed in that participant. It also said the first participant’s threads had stabilized and performance had recovered. These were company reports at that date.
Blindsight receives a development designation, according to Neuralink
Neuralink announced FDA Breakthrough Device designation for its Blindsight project for people with vision impairment. The FDA explains that designation helps accelerate development and review, while separate safety and effectiveness standards still apply to marketing authorisation.
The company said Health Canada had authorised CAN-PRIME and opened recruitment. It described a study of the implant and robot's safety and initial functionality, rather than a commercial treatment launch.
CONVOY extends research toward an assistive robotic arm
Neuralink announced approval and launch of a feasibility study using the N1 implant with an investigational assistive robotic arm. The design allowed participants in PRIME to enrol in the additional study.
A speech project receives Breakthrough designation, the company says
Neuralink announced FDA Breakthrough Device designation for a project intended to assist communication in people with severe speech impairment. The designation alone did not establish that the device could be marketed or that its proposed benefits had been proven.
The company announced a USD 650 million Series E round to support its work. A financing announcement is distinct from a regulatory assessment of the technology.
Neuralink announced approvals for GB-PRIME and recruitment through University College London Hospitals and Newcastle upon Tyne Hospitals. The study again focused on safety and initial functionality.
Neuralink's registered VOICE protocol records 3 October as the actual study start. It describes early feasibility research into initial safety and communication using the N1 implant and R1 robot. The registry entry was first posted on 4 November, after the start date.
The company reports 21 trial participants worldwide
Neuralink's two-year update reported 21 participants enrolled in trials worldwide and described experience with digital control and assistive devices. These were sponsor-reported observations, not a conclusion that the technology was proven safe or effective for general use.
Neuralink reports work to reduce repeated calibration
The company described participant-specific models trained on previously collected neural recordings, reporting longer-lasting cursor control in early use. It also said that pooling data across participants had not yet improved live performance over individual models. These are sponsor-reported engineering results, not proof of general clinical benefit.
A VOICE participant helps test communication prototypes
Neuralink reported a 72-hour engineering session testing features for its Bloom speech app, including automatic start and stop detection, text editing and phone-call integration. The company described prototypes developed with one trial participant and stated that its devices remained investigational, without marketing approval from the FDA or other regulators.
Coverage through 29 October 2026. Editorial review: 3 November 2026. Spotted an error? See corrections. Copyright concerns: report an asset. Every event links to its sources. Source type does not establish whether a claim is true.